Author:
Kjoller Erik,Hilden Jorgen,Winkel Per,Frandsen Niels J.,Galatius Soren,Jensen Gorm,Kastrup Jens,Hansen Jorgen Fischer,Kolmos Hans J.,Jespersen Christian M.,Hildebrandt Per,Gluud Christian
Reference27 articles.
1. Clinical trials—multiple treatments, multiple end points, and multiple lessons;Lauer;JAMA,2003
2. U.S. Department of Health and Human Services—Food and Drug Administration. Guidance for Clinical Trial Sponsors Establishment and Operation of Clinical Trial Data Monitoring Committees. 2006:1–38. Available at http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf. Accessed November 13, 2011.
3. Committee for Medicinal Products for Human Use—European Medicines Agency (EMA). Guideline on Data Monitoring Committees. 2005:1–8. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003635.pdf. Accessed November 13, 2011.
4. Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal;Dechartres;J Clin Epidemiol,2009
5. Cardiovascular outcome ascertainment was similar using blinded and unblinded adjudicators in a national prospective study;Parmar;J Clin Epidemiol,2010
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献